BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38349740)

  • 1. PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice.
    Frijlink E; Bosma DM; Busselaar J; Battaglia TW; Staal MD; Verbrugge I; Borst J
    J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38349740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
    Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells.
    Dilek N; Poirier N; Hulin P; Coulon F; Mary C; Ville S; Vie H; Clémenceau B; Blancho G; Vanhove B
    PLoS One; 2013; 8(12):e83139. PubMed ID: 24376655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD86 Is a Selective CD28 Ligand Supporting FoxP3+ Regulatory T Cell Homeostasis in the Presence of High Levels of CTLA-4.
    Halliday N; Williams C; Kennedy A; Waters E; Pesenacker AM; Soskic B; Hinze C; Hou TZ; Rowshanravan B; Janman D; Walker LSK; Sansom DM
    Front Immunol; 2020; 11():600000. PubMed ID: 33363541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
    Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
    Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of Memory Phenotype T Lymphocyte Homeostasis: Role of Costimulation.
    Panda AK; Kim YH; Shevach EM
    J Immunol; 2022 Feb; 208(4):851-860. PubMed ID: 35039334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
    Kleinpeter P; Remy-Ziller C; Winter E; Gantzer M; Nourtier V; Kempf J; Hortelano J; Schmitt D; Schultz H; Geist M; Brua C; Hoffmann C; Schlesinger Y; Villeval D; Thioudellet C; Erbs P; Foloppe J; Silvestre N; Fend L; Quemeneur E; Marchand JB
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30918073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
    Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
    Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD80 on Human T Cells Is Associated With FoxP3 Expression and Supports Treg Homeostasis.
    Soskic B; Jeffery LE; Kennedy A; Gardner DH; Hou TZ; Halliday N; Williams C; Janman D; Rowshanravan B; Hirschfield GM; Sansom DM
    Front Immunol; 2020; 11():577655. PubMed ID: 33488578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CD28/CTLA-4-B7 signaling pathway is involved in both allergic sensitization and tolerance induction to orally administered peanut proteins.
    van Wijk F; Nierkens S; de Jong W; Wehrens EJ; Boon L; van Kooten P; Knippels LM; Pieters R
    J Immunol; 2007 Jun; 178(11):6894-900. PubMed ID: 17513738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced suppression of polyclonal CD8
    Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
    J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 and CTLA-4 exert additive control of effector regulatory T cells at homeostasis.
    Pereira JA; Lanzar Z; Clark JT; Hart AP; Douglas BB; Shallberg L; O'Dea K; Christian DA; Hunter CA
    Front Immunol; 2023; 14():997376. PubMed ID: 36960049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice.
    Loser K; Scherer A; Krummen MB; Varga G; Higuchi T; Schwarz T; Sharpe AH; Grabbe S; Bluestone JA; Beissert S
    J Immunol; 2005 May; 174(9):5298-305. PubMed ID: 15843526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
    Horn LA; Long TM; Atkinson R; Clements V; Ostrand-Rosenberg S
    Cancer Immunol Res; 2018 Jan; 6(1):59-68. PubMed ID: 29122838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TCR Signaling and CD28/CTLA-4 Signaling Cooperatively Modulate T Regulatory Cell Homeostasis.
    Holt MP; Punkosdy GA; Glass DD; Shevach EM
    J Immunol; 2017 Feb; 198(4):1503-1511. PubMed ID: 28053234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity.
    Watanabe T; Ishino T; Ueda Y; Nagasaki J; Sadahira T; Dansako H; Araki M; Togashi Y
    Cancer Sci; 2023 May; 114(5):1859-1870. PubMed ID: 36762794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.